ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)

ALBERT B. SABIN VACCINE INSTITUTE, INC. specializes in the research, development, and manufacturing of viral vaccine candidates for high-consequence pathogens, with a focus on Ebola and Marburg viruses. The organization leverages advanced biotechnological platforms to produce bulk drug substance and final drug product at scale, supporting preparedness for outbreak scenarios. Their technical expertise includes viral vector design, cell culture optimization, purification processes, and aseptic fill-finish operations tailored for biosafety level 3 environments. A key differentiator is their targeted development of monovalent vaccines against non-Ebola filoviruses, an area of critical unmet need in global health security. The institute demonstrates deep proficiency in translational vaccinology, bridging preclinical research to GMP-compliant manufacturing under federal emergency response frameworks. The contractor maintains a focused relationship with the Department of Health and Human Services, delivering mission-critical vaccine development and production services aligned with public health preparedness objectives. Their work supports HHS’s Biomedical Advanced Research and Development Authority (BARDA) and CDC initiatives, primarily advancing countermeasures for emerging infectious diseases with pandemic potential. This sustained engagement reflects a trusted partnership in biosurveillance and medical countermeasure readiness. The primary NAICS classification of 541714—Research and Development in Biotechnology—reflects their core activity: applied virology and vaccine innovation outside nanobiotechnology. They occupy a niche in filovirus vaccinology, distinguishing themselves through specialized expertise in Sudan ebolavirus and Marburg virus vaccine platforms. Their market positioning is that of a mission-driven biotech developer serving federal biosafety and biodefense priorities. As an 8H-certified entity headquartered in Washington, DC, the institute operates as a small, specialized organization with no additional federal certifications. Its geographic proximity to federal health agencies enhances responsiveness and collaboration, reinforcing its role as a strategic partner in national biothreat preparedness.